OTHER INFORMATION
−Removed: Agreement, dated September 5, 2022, between Elite Pharmaceuticals, Inc.
−Removed: and Kirko Kirkov, incorporated by reference to Exhibit 10.1
−Removed: to the Current Report on Form 8-K filed on September 7, 2022.
−Removed: Certification
−Removed: of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
−Removed: Certification
−Removed: of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
−Removed: Certification
−Removed: of Chief Executive Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
−Removed: Certification
−Removed: of Chief Financial Officer pursuant to 18 U.S.C.
+Added: During the fiscal quarter ended June 30, 2023, none of the Company’s directors or officers (as defined in
+Added: Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule
+Added: 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended).
+Added: Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
+Added: Certification of Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
11 unchanged sentences
of the Board of Directors
−Removed: Executive Officer)
−Removed: Financial Officer
−Removed: Accounting and Financial Officer)
+Added: Executive Officer, Principal Financial Officer, and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.